PCCTC c16-168: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) with DNA Repair Defects
Aims: The main purpose is to study abiraterone alone, olaparib alone or the combination of the two drugs to see which works better.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17/285
Sponsor: University of Chicago/PCCTC
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes
NRG GU-008: A Randomized Phase III Trial Incorporating Abiraterone Acetate and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)
Aims: The main purpose is to study is to see if we can lengthen the time without your prostate cancer spreading by adding 2 new hormone therapy drugs to the usual combination of hormone therapy and radiation therapy.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH21-206
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes
EA8183: A Phase III Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Aims: The main purpose is to study is to see if adding daralutamide to standard androgen deprivation therapy is better than standard androgen deprivation therapy alone and preventing cancer from recurring.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH21-133
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes
CURLu177PSM0001: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Aims: The purpose of this study is to assess the potential safety and effectives of the investigational radio-isotope, 177Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH22-020
Sponsor: Curium US LLC
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes
UC13-0540: Afatinib (BIBW 2992) in Advanced Refractory Urothelial Cancer
Aims: The main purpose of this study is to see the effects (good and/or bad) that experimental drug, afatinib, has on you and your urothelial cancer.
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH21-303
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment:Yes
S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy wiht or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Aims: The main purpose of this study is to see the effects (good and/or bad) that experimental drug, atezolizumab, has on you and your bladder cancer when given with standard of care therapy.
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH22-059
Sponsor: SWOG
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment:Yes
S2011: Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle Invasive Urothelial Carcinoma
Aims: The main purpose of this study is to see the effects (good and/or bad) of chemotherapy and immunotherapy versus no therapy prior to surgery on you and your bladder cancer.
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH22-054
Sponsor: SWOG
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment:Yes
UC13-0540: TiNivo-2: A Phase 3, Randomized, Controlled,Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
Aims: The main purpose of this study is to see the effects (good and/or bad) that experimental drug, Tivzanib, has on you and your urothelial cancer, either when given alone or with nivolumab.
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH21-353
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Kate Quigley at 847.570.2698
Open to Enrollment:Yes
Genomic Profiling and Clinical Outcomes in Metastatic Castrate-Resistant Prostate Cancer
Aims: The main purpose of this study is to see if genomic testing in men with metatstatic castration resistance prostate cancer is clinically relevant and if it will help guide physician decision making.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH20-300
Sponsor: NorthShore
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment:Yes
J1557: Overcoming Drug Resistance in Metastatic Castration-Resitant Prostate Cancer with Novel Combination of TGF-G Recepto Inhibitor LY2157299 and Enzalutamide: A Randomized, Multi-Site Phase II Study
Aims: The purpose is to test the effectiveness and safety of combining enzalutamide with LY2157299 in men with advanced castrate resistant prostate cancer.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH19-186
Sponsor: Johns Hopkins University
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes